Scientific Advisor Henning Beck Nielsen, as well as COO Lars B. Rasmussen have both decided to step out of their current PILA roles to focus more on other projects outside the company.
“I, sincerely, thank them both for their tremendous contribution in developing PILA to its current stage. Together with Henning Beck-Nielsen we laid out and executed a plan to take our new Mode of Action oral diabetes agent, XEN-D0501, into first clinical trials in patients with type 2 diabetes. Together with Lars B. Rasmussen, we have listed PILA on Nasdaq First North GM in Stockholm, Sweden which have permitted our further successful development towards phase 2b results,“ says Dorte X. Gram, CEO.
New to the PILA organization is Susanne Rugh, previously Novo Nordisk, who has offered her diabetes drug development expertise and is appointed Project Director for the Diabetes Clinical Development program for XEN-D0501, “XEN-DIA”.
Susanne Rugh has contributed significantly to current diabetes treatment by leading no less than 3 Novo Nordisk development candidates through to registration and marketing (Levemir, Tresiba and Ryzodeg).
“I’m truly grateful that so many past and present skilled individuals and organisations have chosen to dedicate some of their excellence to help PILA onwards! The new collaboration with Susanne Rugh will ensure the coming clinical development of XEN-DIA in accordance to best practice in pharma,” says Dorte X. Gram.
Photo of Susanne Rugh: Pila Pharma